RESUMEN
Hyperhemolysis Syndrome (HHS) is a rare and severe post-transfusion complication characterized by the destruction of both recipient and donor red blood cells (RBC). The underlying mechanism of HHS is not fully understood and proper management can be difficult. Furthermore, there are few reports regarding HHS in pregnancy. We report on the development and management of HHS in a pregnant woman with known compound Sickle cell disease/ß-0-thalassemia after transfusion of not fully compatible packed red blood cells (PRBC). We aim to raise awareness on this diagnostically challenging and life-threatening type of hemolysis with this report, and to stress the need to consider the diagnosis of HHS in SCD patients with progressive anemia despite PRBC administration.
RESUMEN
BACKGROUND AND OBJECTIVES: Non-invasive assays for predicting foetal blood group status in pregnancy serve as valuable clinical tools in the management of pregnancies at risk of detrimental consequences due to blood group antigen incompatibility. To secure clinical applicability, assays for non-invasive prenatal testing of foetal blood groups need to follow strict rules for validation and quality assurance. Here, we present a multi-national position paper with specific recommendations for validation and quality assurance for such assays and discuss their risk classification according to EU regulations. MATERIALS AND METHODS: We reviewed the literature covering validation for in-vitro diagnostic (IVD) assays in general and for non-invasive foetal RHD genotyping in particular. Recommendations were based on the result of discussions between co-authors. RESULTS: In relation to Annex VIII of the In-Vitro-Diagnostic Medical Device Regulation 2017/746 of the European Parliament and the Council, assays for non-invasive prenatal testing of foetal blood groups are risk class D devices. In our opinion, screening for targeted anti-D prophylaxis for non-immunized RhD negative women should be placed under risk class C. To ensure high quality of non-invasive foetal blood group assays within and beyond the European Union, we present specific recommendations for validation and quality assurance in terms of analytical detection limit, range and linearity, precision, robustness, pre-analytics and use of controls in routine testing. With respect to immunized women, different requirements for validation and IVD risk classification are discussed. CONCLUSION: These recommendations should be followed to ensure appropriate assay performance and applicability for clinical use of both commercial and in-house assays.
Asunto(s)
Antígenos de Grupos Sanguíneos , Antígenos de Grupos Sanguíneos/genética , Femenino , Sangre Fetal , Feto , Genotipo , Humanos , Embarazo , Diagnóstico Prenatal , Sistema del Grupo Sanguíneo Rh-Hr/genéticaRESUMEN
Starting in 2013, blood donors must be tested at least using: (1) one monoclonal anti-D and one anti-CDE (alternatively full RhCcEe phenotyping), and (2) all RhD negative donors must be tested for RHD exons 5 and 10 plus one further exonic, or intronic RHD specificity, according to the guidelines of the Blood Transfusion Service of the Swiss Red Cross (BTS SRC). In 2012 an adequate stock of RHD screened donors was built. Of all 25,370 RhD negative Swiss donors tested in 2012, 20,015 tested at BTS Berne and 5355 at BTS Zürich, showed 120 (0.47%) RHD positivity. Thirty-seven (0.15%) had to be redefined as RhD positive. Routine molecular RHD screening is reliable, rapid and cost-effective and provides safer RBC units in Switzerland.
Asunto(s)
Donantes de Sangre/legislación & jurisprudencia , Tipificación y Pruebas Cruzadas Sanguíneas , Selección de Donante , Sistema del Grupo Sanguíneo Rh-Hr/genética , Tipificación y Pruebas Cruzadas Sanguíneas/métodos , Tipificación y Pruebas Cruzadas Sanguíneas/normas , Selección de Donante/legislación & jurisprudencia , Selección de Donante/normas , Femenino , Humanos , Masculino , SuizaRESUMEN
RH1 incompatibility between mother and fetus can cause hemolytic disease of the fetus and newborn. In Switzerland, fetal RHD genotyping from maternal blood has been recommended from gestational age 18 onwards since the year 2020. This facilitates tailored administration of RH immunoglobulin (RHIG) only to RH1 negative women carrying a RH1 positive fetus. Data from 30 months of noninvasive fetal RHD screening is presented. Cell-free DNA was extracted from 7192 plasma samples using a commercial kit, followed by an in-house qPCR to detect RHD exons 5 and 7, in addition to an amplification control. Valid results were obtained from 7072 samples, with 4515 (64%) fetuses typed RHD positive and 2556 (36%) fetuses being RHD negative. A total of 120 samples led to inconclusive results due to the presence of maternal or fetal RHD variants (46%), followed by women being serologically RH1 positive (37%), and technical issues (17%). One sample was typed false positive, possibly due to contamination. No false negative results were observed. We show that unnecessary administration of RHIG can be avoided for more than one third of RH1 negative pregnant women in Switzerland. This reduces the risks of exposure to a blood-derived product and conserves this limited resource to women in actual need.
RESUMEN
This study aims to analyze the Psychological Well-Being among prospective counselors from the Faith-Based Educational Institution during the COVID-19 pandemic. The approach of this study was quantitative with a descriptive method. The Psychological Well-Being among prospective counselors is at a high classification level, namely 84%. The components of Psychological Well-Being that are above the total average score are Positive Relationship with Other People and components of Self-Growth.
Asunto(s)
COVID-19 , Consejeros , Cuidado Pastoral , Humanos , Bienestar Psicológico , Pandemias , Estudios Prospectivos , Brotes de EnfermedadesRESUMEN
COVID-19 makes life more stressful. When we face it alone, it will make us not only stress but can depress. Connect with others through the right group can be the good Coping stress during COVID-19. Even though we cannot go anywhere, we cannot meet each other face to face, but COVID-19 has not defeated our social life.
Asunto(s)
COVID-19 , Cuidado Pastoral , Adaptación Psicológica , Humanos , Pandemias , SARS-CoV-2RESUMEN
COVID-19 cannot rob us of our ability to perform our ministry for children. As adults and ministers, we can show our support for the spiritual growth of children. COVID-19 has not deprived us of our creativity in praise, telling of God's love, prayers, and support for all the children and parents. COVID-19 has not defeated our spiritual life.